IMM 101

Drug Profile

IMM 101

Alternative Names: Heat-killed whole cell Mycobacterium obuense; IMM-101

Latest Information Update: 14 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Immodulon Therapeutics
  • Developer HCA International; Immodulon Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer; Pancreatic cancer
  • Phase I/II Cancer; Malignant melanoma

Most Recent Events

  • 02 Jun 2017 Pharmacodynamics data from preclinical studies in Breast cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 May 2017 Phase-I/II clinical trials in Cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease) in United Kingdom (Intradermal) (NCT03009058)
  • 30 Dec 2016 Immodulon Therapeutics plans the phase I/IIa MODULATE trial for Cancer (Combination therapy, Metastatic disease, Inoperable/Unresectable) in United Kingdom and France (Intradermal) (NCT03009058)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top